Cover
Vol. 10 No. 2 (2020)

Published: August 31, 2020

Pages: 1-13

Research Article

Correlation between Post-Tamoxifen Hormonal Changes and Seminal Fluid Analysis Parameters Improvement .

Ali Abdulkhaleq 1 Ula Al-kawaz
1High Institute of Infertility Diagnosis and Assisted Reproductive Technologies, Al Nahrain University, Baghdad, Iraq.
History
  • Received: July 7, 2020
  • Accepted: July 30, 2020
  • Available Online: August 8, 2020
DOI

https://doi.org/10.28969/IJEIR.v10.i2.r1.20

Abstract

Oligoasthenoteratozoospermia is a prevalent cause of male infertility. (iOAT). It is generally acknowledged that, due to the fact that spermatogenesis is a sex-hormone-dependent process, specific endocrine treatments might enhance or recover male fertility. The typical negative feedback of sex steroids is disrupted by anti-estrogen medication, leading to a rise in endogenous gonadotropin-releasing hormone secretion (FSH and LH) straight from the pituitary. The stimulation of Leydig cells in the testes by FSH and LH is thought to promote local testosterone synthesis, which in turn may improve spermatogenesis. The study sample consisted of 42 iOAT patients. Baseline seminal fluid analysis (SFA) and hormonal assessment (FSH, LH, prolactin, and testosterone) were taken. Each patient was given medical treatment with tamoxifen (20 mg/day) for three months. SFA, FSH, and testosterone were taken after three months. There was a significant increase in FSH, testosterone, sperm concentration, and progressive motility after treatment (p value <0.001), furthermore, there was no significant correlation between hormonal changes and changes in SFA study markers (p value > 0,05). Improvements in hormone levels following tamoxifen treatment for patients with idiopathic oligoasthenoteratospermia do not correlate with alterations in SFA markers.

Keywords

References

  1. Guo L, Jing J, Ming Y, Bing F, Tamoxifen TAM. Tamoxifen is a potent antioxidant modulator for sperm quality in patients with idiopathic oligoasthenospermia. Int Urol Nephrol. 2015 ;
  2. Choy JT, Eisenberg ML. Male infertility as a window to health. Fertil Steril. 2018 Oct;110 (5):810–4 .
  3. Jensen CFS, Østergren P, Dupree JM, Ohl DA, Sønksen J, Fode M. Varicocele and male infertility. Nat Rev Urol. 2017 Sep;14 (9):523–33 .
  4. Katib A. Mechanisms linking obesity to male infertility. Cent Eur J Urol. 2015;68 (1):79–85 .
  5. Krausz C, Riera-Escamilla A. Genetics of male infertility. Nat Rev Urol. 2018 Jun;15 (6):369–84 .
  6. Duca Y, Calogero AE, Cannarella R, Condorelli RA, La Vignera S. Current, and emerging medical therapeutic agents for idiopathic male infertility. Expert opinion on pharmacotherapy. 2019 Jan 2;20 (1):55- 67.11. [7] Plouffe LEO, Siddhanti S. The Effect of Selective Estrogen Receptor Modulators on Parameters of the Hypothalamic-Pituitary-Gonadal Axis. :251– 8 .
  7. Kumar R, Gautam G, Gupta NP. Drug Therapy for Idiopathic Male Infertility : Rationale Versus Evidence. 2006;176 (October):1307–12 .
  8. Cocuzza M, Agarwal A. Nonsurgical treatment of male infertility: specific and empiric therapy. Biologics. 2007 Sep;1 (3):259–69 .
  9. Skorupskaite K, George JT, Anderson RA. The kisspeptin-GnRH pathway in human reproductive health and disease. Hum Reprod Update. 2014;20 (4):485–500 .
  10. Cooper T, Castilla JA. WHO laboratory manual for the examination and processing of human semen. InJournal of Andrology 2009 Mar 1 (Vol. 30, pp. 9-9). C/O ALLEN PRESS, INC. PO BOX 368, LAWRENCE, KS 66044 USA: AMER SOC ANDROLOGY, INC .
  11. Jarow JP, Zirkin BR. The androgen microenvironment of the human testis and hormonal control of spermatogenesis. Ann N Y Acad Sci. 2005 Dec;1061:208–20 .
  12. Neto FTL, Bach PV, Najari BB, Li PS, Goldstein M. Spermatogenesis in humans and its affecting factors. Semin Cell Dev Biol. 2016 Nov;59:10–26 .
  13. Taylor P, Ramaswamy S, Weinbauer GF. Endocrine control of spermatogenesis : Role of FSH and LH / testosterone. 2015; (March):37–41 .
  14. Walker WH, Cheng J. FSH and testosterone signaling in Sertoli cells. Reproduction. 2005 Jul;130 (1):15–28 .
  15. Zhao N, Lan X, Jun L, Li T, Min J. Treatment of idiopathic oligozoospermia with combined human chorionic gonadotropin / human menopausal gonadotrophin : A randomised, double-blinded, placebo- controlled clinical study. 2019; (February):1– 9 .
  16. Lunenfeld, B., Olchovsky, D., Tadir, Y., & Glezerman, M. (1979). Treatment of male infertility with human gonadotrophins: Selection of cases, management, and results. Andrologia, 11 (5), 331-336 .
  17. Knuth UA, Hönigl W, Bals-Pratsch M, Schleicher G, Nieschlag E. Treatment of severe oligospermia with human chorionic gonadotropin/human menopausal gonadotropin: a placebo-controlled, double- blind trial. J Clin Endocrinol Metab. 1987 Dec;65 (6):1081–7 .
  18. Schill WB, Jüngst D, Unterburger P, Braun S. Combined hMG/hCG treatment in subfertile men with idiopathic normogonadotrophic oligozoospermia. Int J Androl. 1982 Oct;5 (5):467–77 .
  19. Behre HM, Greb RR, Mempel A, Sonntag B, Kiesel L, Kaltwaßer P, et al. Significance of a common single nucleotide polymorphism in exon 10 of the follicle- stimulating hormone ( FSH ) receptor gene for the ovarian response to FSH : a pharmacogenetic approach to controlled ovarian hyperstimulation. :451–6 .
  20. Simoni M, Santi D, Negri L, Hoffmann I, Muratori M, Baldi E, et al. Treatment with human, recombinant FSH improves sperm DNA fragmentation in idiopathic infertile men depending on the FSH receptor polymorphism p.N680S: A pharmacogenetic study. Hum Reprod. 2016;31 (9):1960–9 .
  21. Nordhoff V, Sonntag B, von Tils D, Götte M, Schüring AN, Gromoll J, et al. Effects of the FSH receptor gene polymorphism p.N680S on cAMP and steroid production in cultured primary human granulosa cells. Reprod Biomed Online. 2011 Aug;23 (2):196–203 .
  22. Lu DİMTUĞ. Aromatase inhibitors in infertile patients : effects on seminal parameters, serum, and seminal plasma testosterone levels, and estradiol levels during short-term follow-up Aromatase inhibitors in infertile patients : effects on seminal parameters, serum. 2009;39 (4):1–7 .
  23. Bibancos M, Cavagnoli M, Bonetti TCS, Semaco E, Motta ELA, Serafini PC. Letrozole Therapy for Obstructive Azoospermic Men before in vitro Fertilization (IVF) treatment with Percutaneous Epididymal Sperm Aspiration. JBRA Assist Reprod. 2015 Nov;19 (4):230–4 .
  24. Cavallini G, Beretta G, Biagiotti G. Preliminary study of letrozole use for improving spermatogenesis in non- obstructive azoospermia patients with normal serum FSH. Asian J Androl [Internet]. 2011;13 (6):895–7. Available from: http://dx.doi.org/10.1038/aja.2011.44
  25. Cavallini G, Biagiotti G, Bolzon E. Multivariate analysis to predict letrozole efficacy in improving sperm count of non- obstructive azoospermic and cryptozoospermic patients: a pilot study. Asian J Androl. 2013 Nov;15 (6):806–11 .
  26. Saylam B, Efesoy O, Cayan S. The effect of aromatase inhibitor letrozole on body mass index, serum hormones, and sperm parameters in infertile men. Fertil Steril. 2011 Feb;95 (2):809–11 .
  27. Kooshesh L, Bahmanpour S, Zeighami S, Nasr-esfahani MH. Effect of Letrozole on sperm Parameters, Chromatin Status, and ROS level in idiopathic Oligo / Astheno / Teratozoospermia. 2020;2:1–9 .
  28. Males I, Emqn EAA, Protocol PCR, Abdulwahid MJ, Al-attar MS. Molecular Diagnosis of Y-Chromosome Microdeletions in Some Kurdish. 2022 ;
  29. Jawed HM, Jebur MS. The impact of gram-positive bacteria on semen quality in infertile men and assessment antibiotic Susceptibility profile. Al-Nisour Journal for Medical Sciences. 2022;4 ( 1 .)
  30. Jayasena CN, Radia UK, Figueiredo M, Revill LF, Dimakopoulou A, Osagie M, et al. Reduced Testicular Steroidogenesis and Increased Semen Oxidative Stress in Male Partners as Novel Markers of Recurrent Miscarriage. Clin Chem. 2019 Jan;65 (1):161–9 .
  31. Darbandi M, Darbandi S, Agarwal A, Sengupta P, Durairajanayagam D. Reactive oxygen species and male reproductive hormones. 2018;1–14 .
  32. Aitken RJ, Roman SD. Antioxidant systems and oxidative stress in the testes (Reprinted from Molecular Mechanisms in Spermatogenesis, 2007). Oxid Med Cell Longev. 2008;1 (1):15–24 .